Holen Sie sich die Stockscreener-App
86.53
0.62%
0.53
Handel nachbörslich:
86.53
Schlusskurs vom Vortag:
$86.00
Offen:
$85.86
24-Stunden-Volumen:
5.48M
Relative Volume:
3.07
Marktkapitalisierung:
$16.90B
Einnahmen:
$4.58B
Nettoeinkommen (Verlust:
$870.87M
KGV:
19.67
EPS:
4.4
Netto-Cashflow:
$945.58M
1W Leistung:
+4.13%
1M Leistung:
+1.25%
6M Leistung:
+43.40%
1J Leistung:
+29.50%
1-Tages-Spanne:
$85.31
$86.81
1-Wochen-Bereich:
$82.72
$86.81
52-Wochen-Spanne:
$53.56
$87.99
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
86.53 | 16.79B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte (NASDAQ:INCY) EVP Sheila Denton Sells 278 Shares - MarketBeat
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN
Guggenheim Reiterates Neutral Rating for Incyte (INCY) | INCY Stock News - GuruFocus
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - Yahoo
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In ChildrenIncyte (NASDAQ:INCY) - Benzinga
Incyte (NASDAQ:INCY) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Invst LLC Makes New $315,000 Investment in Incyte Corporation $INCY - MarketBeat
CEO Change: Is Incyte Corporation showing insider buyingMarket Activity Summary & Advanced Technical Signal Analysis - khodrobank.com
Loss Report: What is the next catalyst for Incyte CorporationJuly 2025 Decliners & Target Return Focused Stock Picks - khodrobank.com
FDA approves Opzelura for atopic dermatitis in children ages 2 and up - Investing.com
US FDA approves Incyte's eczema cream for pediatric patients - Reuters
FDA Approves Incyte's (INCY) Opzelura Cream for Pediatric Dermatitis - GuruFocus
FDA Greenlights Incyte's Opzelura Cream for Pediatric Dermatitis Treatment - GuruFocus
Incyte gets FDA nod for Opzelura cream in atopic dermatitis treatment - Seeking Alpha
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis - Business Wire
Incyte stock rating reiterated by Citizens JMP amid promising drug data - Investing.com
Incyte Corporation $INCY Shares Acquired by Sivia Capital Partners LLC - MarketBeat
Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT - Yahoo
INCY Announces New Late-Stage Data on Skin Disease Drug - Yahoo Finance
Retail Trends: Is JZXN in a long term uptrend2025 Earnings Surprises & Low Risk Entry Point Tips - خودرو بانک
Povorcitinib shows promising results for hidradenitis suppurativa By Investing.com - Investing.com Canada
Is Incyte Corporation impacted by rising ratesPortfolio Value Report & Free Verified High Yield Trade Plans - خودرو بانک
INCY: Incyte Unveils Promising Interim Data for Povorcitinib in Phase 3 Trials - GuruFocus
Incyte’s povorcitinib shows strong results in hidradenitis suppurativa trial - Investing.com
Alliancebernstein L.P. Has $14.55 Million Stake in Incyte Corporation $INCY - MarketBeat
Povorcitinib shows promising results for hidradenitis suppurativa - Investing.com
Severe Asthma Market Insights Highlight Expanding Outlook Till - openPR.com
60% Patient Response: Incyte's New Drug Shows Strong Promise in Treating Severe Skin Disease at 24 Weeks - Stock Titan
Incyte Corporation $INCY Stock Position Raised by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
Severe Asthma Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Sanofi, GlaxoSmithKline, EMS, Oneness Biotech, Incyte Corp, CSPC ZhongQi Pharma, AstraZeneca - Barchart.com
OMNI 360 Wealth Inc. Acquires New Stake in Incyte Corporation $INCY - MarketBeat
Kera Capital Partners Inc. Invests $339,000 in Incyte Corporation $INCY - MarketBeat
Royal Bank of Canada Sells 14,218 Shares of Incyte Corporation $INCY - MarketBeat
Ashton Thomas Private Wealth LLC Raises Position in Incyte Corporation $INCY - MarketBeat
5,260 Shares in Incyte Corporation $INCY Bought by MBB Public Markets I LLC - MarketBeat
Polycythemia Vera Market: Epidemiology, Treatment Landscape, and Key Players | Incyte, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfa - Barchart.com
Update Recap: Is Incyte Corporation impacted by rising ratesPrice Action & Daily Volume Surge Signals - khodrobank.com
Woodline Partners LP Grows Holdings in Incyte Corporation $INCY - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $95.86 Million Stock Holdings in Incyte Corporation $INCY - MarketBeat
Empowered Funds LLC Buys 115,225 Shares of Incyte Corporation $INCY - MarketBeat
Great Lakes Advisors LLC Grows Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation (NASDAQ:INCY) Sees Large Growth in Short Interest - MarketBeat
Incyte Corporation $INCY Shares Sold by Amundi - MarketBeat
Incyte Corporation $INCY Shares Acquired by Acadian Asset Management LLC - MarketBeat
Raymond James Financial Inc. Buys 17,313 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Corporation (INCY) Advances KRAS Cancer Program - Yahoo Finance
Caxton Associates LLP Takes $1.67 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation $INCY Stock Position Raised by Jacobs Levy Equity Management Inc. - MarketBeat
Incyte Corporation $INCY Shares Acquired by Federation des caisses Desjardins du Quebec - MarketBeat
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress - Business Wire
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):